LNSR · LENSAR Inc. Common Stock
View on chartInsiders & Stakes
| Nicholas T. Curtis Chief Executive Officer | ▲ Buy | Grant | 1,122,758 Shares held | 6/3/2026 | View profile |
| William J. Link, PhD Director | ▲ Buy | Grant | 568,062 Shares held | 6/3/2026 | View profile |
| Alan B. Connaughton Chief Operating Officer | ▲ Buy | Grant | 389,173 Shares held | 6/3/2026 | View profile |
| Richard L. Lindstrom, MD Director | ▲ Buy | Grant | 263,831 Shares held | 6/3/2026 | View profile |
| Thomas R. Staab II Chief Financial Officer | ▼ Sell | Tax Withholding | 174,609 Shares held | 5/6/2026 | View profile |
| Aimee S. Weisner Director | ▲ Buy | Grant | 110,368 Shares held | 6/3/2026 | View profile |
| Gary M. Winer Director | ▲ Buy | Grant | 105,635 Shares held | 6/3/2026 | View profile |
| Elizabeth G. O'Farrell Director | ▲ Buy | Grant | 67,368 Shares held | 6/3/2026 | View profile |
| Kendra Wong Principal Accounting Officer | ▲ Buy | Grant | 56,481 Shares held | 6/3/2026 | View profile |
| Todd B. Hammer Director | ▲ Buy | Grant | 56,083 Shares held | 6/3/2026 | View profile |
| Thomas B. Ellis Director | ▲ Buy | Grant | 56,083 Shares held | 6/3/2026 | View profile |
| MCLAUGHLIN JOHN PETER Director | ▲ Buy | Grant | 53,631 Shares held | 5/25/2023 | View profile |
Transaction History
| Todd B. Hammer | ▲ Buy | Grant | 17,421 | $0 | 6/3/2026 |
| Thomas B. Ellis | ▲ Buy | Grant | 17,421 | $0 | 6/3/2026 |
| Kendra Wong | ▲ Buy | Grant | 13,066 | $0 | 6/3/2026 |
| Alan B. Connaughton | ▲ Buy | Grant | 34,843 | $0 | 6/3/2026 |
| Nicholas T. Curtis | ▲ Buy | Grant | 130,662 | $0 | 6/3/2026 |
| Aimee S. Weisner | ▲ Buy | Grant | 17,421 | $0 | 6/3/2026 |
| Elizabeth G. O'Farrell | ▲ Buy | Grant | 17,421 | $0 | 6/3/2026 |
| Gary M. Winer | ▲ Buy | Grant | 17,421 | $0 | 6/3/2026 |
| Richard L. Lindstrom, MD | ▲ Buy | Grant | 17,421 | $0 | 6/3/2026 |
| William J. Link, PhD | ▲ Buy | Grant | 17,421 | $0 | 6/3/2026 |
| Nicholas T. Curtis | ▼ Sell | Other | 0 | $0 | 5/6/2026 |
| Alan B. Connaughton | ▼ Sell | Tax Withholding | 2,739 | $15K | 5/6/2026 |
| Thomas R. Staab II | ▼ Sell | Tax Withholding | 1,350 | $7K | 5/6/2026 |
| Kendra Wong | ▼ Sell | Tax Withholding | 864 | $5K | 5/6/2026 |
| Thomas R. Staab II | ▲ Buy | Option Exercise | 5,500 | $15K | 3/19/2026 |
| Alan B. Connaughton | ▼ Sell | Tax Withholding | 2,392 | $27K | 2/18/2026 |
| Thomas R. Staab II | ▼ Sell | Tax Withholding | 1,076 | $12K | 2/18/2026 |
| Nicholas T. Curtis | ▼ Sell | Other | 0 | $0 | 2/18/2026 |
| Nicholas T. Curtis | ▼ Sell | Other | 0 | $0 | 1/11/2026 |
| Thomas R. Staab II | ▼ Sell | Tax Withholding | 1,826 | $21K | 1/11/2026 |
| Alan B. Connaughton | ▼ Sell | Tax Withholding | 2,262 | $26K | 1/11/2026 |
| Thomas B. Ellis | ▲ Buy | Grant | 7,374 | $0 | 5/23/2025 |
| Todd B. Hammer | ▲ Buy | Grant | 7,374 | $0 | 5/23/2025 |
| Aimee S. Weisner | ▲ Buy | Grant | 7,374 | $0 | 5/23/2025 |
| Elizabeth G. O'Farrell | ▲ Buy | Grant | 7,374 | $0 | 5/23/2025 |
| Gary M. Winer | ▲ Buy | Grant | 7,374 | $0 | 5/23/2025 |
| William J. Link, PhD | ▲ Buy | Grant | 7,374 | $0 | 5/23/2025 |
| Richard L. Lindstrom, MD | ▲ Buy | Grant | 7,374 | $0 | 5/23/2025 |
| Alan B. Connaughton | ▲ Buy | Grant | 37,234 | $0 | 2/18/2025 |
| Thomas R. Staab II | ▲ Buy | Grant | 12,766 | $0 | 2/18/2025 |
| Kendra Wong | ▲ Buy | Grant | 6,383 | $0 | 2/18/2025 |
| Nicholas T. Curtis | ▲ Buy | Grant | 127,660 | $0 | 2/18/2025 |
| Kendra Wong | ▼ Sell | Tax Withholding | 1,132 | $9K | 1/11/2025 |
| Thomas R. Staab II | ▼ Sell | Tax Withholding | 1,839 | $15K | 1/11/2025 |
| Gary M. Winer | ▲ Buy | Open Market | 685 | $3K | 9/3/2024 |
| Gary M. Winer | ▲ Buy | Open Market | 1,000 | $4K | 8/28/2024 |
| Gary M. Winer | ▲ Buy | Open Market | 500 | $2K | 8/27/2024 |
| Gary M. Winer | ▲ Buy | Open Market | 802 | $4K | 8/26/2024 |
| Gary M. Winer | ▲ Buy | Open Market | 2 | $9 | 8/22/2024 |
| Gary M. Winer | ▲ Buy | Open Market | 500 | $2K | 8/21/2024 |
| Gary M. Winer | ▲ Buy | Open Market | 500 | $2K | 8/20/2024 |
| Gary M. Winer | ▲ Buy | Open Market | 6 | $24 | 8/16/2024 |
| Gary M. Winer | ▲ Buy | Open Market | 1,000 | $4K | 8/14/2024 |
| Gary M. Winer | ▲ Buy | Open Market | 500 | $2K | 8/12/2024 |
| Thomas R. Staab II | ▲ Buy | Option Exercise | 3,500 | $9K | 8/8/2024 |
| Thomas B. Ellis | ▲ Buy | Grant | 22,000 | $0 | 5/7/2024 |
| William J. Link, PhD | ▲ Buy | Grant | 22,000 | $0 | 5/7/2024 |
| Gary M. Winer | ▲ Buy | Grant | 22,000 | $0 | 5/7/2024 |
| Elizabeth G. O'Farrell | ▲ Buy | Grant | 22,000 | $0 | 5/7/2024 |
| Richard L. Lindstrom, MD | ▲ Buy | Grant | 22,000 | $0 | 5/7/2024 |
| Todd B. Hammer | ▲ Buy | Grant | 22,000 | $0 | 5/7/2024 |
| Aimee S. Weisner | ▲ Buy | Grant | 22,000 | $0 | 5/7/2024 |
| Nicholas T. Curtis | ▲ Buy | Grant | 71,400 | $0 | 5/6/2024 |
| Kendra Wong | ▲ Buy | Grant | 14,200 | $0 | 5/6/2024 |
| Thomas R. Staab II | ▲ Buy | Grant | 19,000 | $0 | 5/6/2024 |
| Alan B. Connaughton | ▲ Buy | Grant | 45,000 | $0 | 5/6/2024 |
| Thomas R. Staab II | ▼ Sell | Tax Withholding | 1,853 | $8K | 1/11/2024 |
| Alan B. Connaughton | ▼ Sell | Tax Withholding | 2,262 | $10K | 1/11/2024 |
| Gary M. Winer | ▲ Buy | Open Market | 300 | $630 | 11/22/2023 |
| Gary M. Winer | ▲ Buy | Open Market | 1,000 | $2K | 11/16/2023 |
| Gary M. Winer | ▲ Buy | Open Market | 500 | $1K | 11/15/2023 |
| Gary M. Winer | ▲ Buy | Open Market | 1,000 | $2K | 11/10/2023 |
| Gary M. Winer | ▲ Buy | Open Market | 705 | $3K | 8/11/2023 |
| Gary M. Winer | ▲ Buy | Open Market | 1,000 | $4K | 8/10/2023 |
| Todd B. Hammer | ▲ Buy | Grant | 9,288 | $0 | 5/25/2023 |
| MCLAUGHLIN JOHN PETER | ▲ Buy | Grant | 9,288 | $0 | 5/25/2023 |
| Elizabeth G. O'Farrell | ▲ Buy | Grant | 9,288 | $0 | 5/25/2023 |
| William J. Link, PhD | ▲ Buy | Grant | 9,288 | $0 | 5/25/2023 |
| Gary M. Winer | ▲ Buy | Grant | 9,288 | $0 | 5/25/2023 |
| Richard L. Lindstrom, MD | ▲ Buy | Grant | 9,288 | $0 | 5/25/2023 |
| Aimee S. Weisner | ▲ Buy | Grant | 9,288 | $0 | 5/25/2023 |
| Thomas B. Ellis | ▲ Buy | Grant | 9,288 | $0 | 5/25/2023 |
| Aimee S. Weisner | ▲ Buy | Open Market | 16,647 | $46K | 5/22/2023 |
| Aimee S. Weisner | ▲ Buy | Open Market | 22,153 | $57K | 5/19/2023 |
| Aimee S. Weisner | ▲ Buy | Open Market | 7,700 | $20K | 5/18/2023 |
| Aimee S. Weisner | ▲ Buy | Open Market | 3,500 | $8K | 5/17/2023 |
| Nicholas T. Curtis | ▲ Buy | Grant | 22,186 | $0 | 1/11/2023 |
| Kendra Wong | ▲ Buy | Grant | 8,490 | $0 | 1/11/2023 |
| Alan B. Connaughton | ▲ Buy | Grant | 15,530 | $0 | 1/11/2023 |
| Thomas R. Staab II | ▲ Buy | Grant | 6,656 | $0 | 1/11/2023 |
| Thomas R. Staab II | ▲ Buy | Open Market | 727 | $2K | 12/7/2022 |
| Thomas R. Staab II | ▲ Buy | Open Market | 2,025 | $6K | 12/6/2022 |
| Gary M. Winer | ▲ Buy | Open Market | 976 | $4K | 11/23/2022 |
| Gary M. Winer | ▲ Buy | Open Market | 1,524 | $5K | 11/22/2022 |
| Gary M. Winer | ▲ Buy | Open Market | 1,500 | $6K | 11/17/2022 |
| Gary M. Winer | ▲ Buy | Open Market | 1,000 | $4K | 11/16/2022 |
| Gary M. Winer | ▲ Buy | Open Market | 2,000 | $12K | 8/18/2022 |
| Gary M. Winer | ▲ Buy | Open Market | 1,000 | $6K | 8/17/2022 |
| Gary M. Winer | ▲ Buy | Open Market | 2,000 | $12K | 8/17/2022 |
| William J. Link, PhD | ▲ Buy | Grant | 4,285 | $0 | 5/25/2022 |
| Aimee S. Weisner | ▲ Buy | Grant | 4,285 | $0 | 5/25/2022 |
| Richard L. Lindstrom, MD | ▲ Buy | Grant | 4,285 | $0 | 5/25/2022 |
| MCLAUGHLIN JOHN PETER | ▲ Buy | Grant | 4,285 | $0 | 5/25/2022 |
| Elizabeth G. O'Farrell | ▲ Buy | Grant | 4,285 | $0 | 5/25/2022 |
| Gary M. Winer | ▲ Buy | Grant | 4,285 | $0 | 5/25/2022 |
| Alan B. Connaughton | ▲ Buy | Grant | 15,000 | $0 | 1/11/2022 |
| Thomas R. Staab II | ▲ Buy | Grant | 15,000 | $0 | 1/11/2022 |
| Nicholas T. Curtis | ▲ Buy | Grant | 30,000 | $0 | 1/11/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Lucid Capital Markets Begins Coverage of LENSAR, Sets $11 Target
Lucid Capital Markets has started coverage on LENSAR and issued a positive rating. The firm set a price target of $11, which sits near the upper end of the company’s 52‑week range. The new outlook may attract attention from investors looking at LENSAR’s valuation relative to its peers. The coverage adds a fresh perspective to the market’s view of the stock.
Lucid Capital Markets Begins Coverage of LENSAR, Sets $11 Target. Lucid Capital Markets has started coverage on LENSAR and issued a positive rating. The firm set a price target of $11, which sits near the upper end of the company’s 52‑week range. The new outlook may attract attention from investors looking at LENSAR’s valuation relative to its peers. The coverage adds a fresh perspective to the market’s view of the stock.